CTOs on the Move

Akero Therapeutics

www.akerotx.com

 
Akero Therapeutics is developing best-in-class medicines that restore metabolic balance to treat non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.akerotx.com
  • 170 Harbor Way 3rd Floor
    South San Francisco, CA USA 94080
  • Phone: 650.487.6488

Executives

Name Title Contact Details
Scott Gangloff
Chief Technology Officer Profile

Funding

Akero Therapeutics raised $65M on 06/25/2018
Akero Therapeutics raised $70M on 12/12/2018

Similar Companies

Suitx

suitX develops robotic exoskeletons for the medical and industrial markets. The Phoenix is the world`s lightest and most advanced medical exoskeleton designed to help people with mobility disorders to be upright and mobile. MAX (Modular Agile Exoskeleton) increases productivity while decreasing the risk of injury by reducing muscle strain on employees working in an industrial setting.

Koronis Pharmaceuticals

Koronis Pharmaceuticals is a Redmond, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Biochrom

Biochrom is a Holliston, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Exonics Therapeutics

Exonics Therapeutics was launched in February 2017 to advance the research of our scientific founder, Dr. Eric Olson and his laboratory at the University of Texas Southwestern Medical Center (UTSW) to develop treatments for patients with neuromuscular diseases. Dr. Olson is one of the world’s leading experts in the study of muscle cells and the application of gene editing to treat these types of diseases. In particular, Dr. Olson’s laboratory has used adeno-associated virus (AAV) to deliver a CRISPR/Cas9 technology that can identify and repair exon mutations to restore the production of dystrophin, a protein that helps stabilize and protect muscle fibers. Dystrophin is the protein missing in boys with Duchenne. The loss of dystrophin causes Duchenne.

Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company focused on discovering, developing and delivering innovative medicines for patients with serious and life-threatening diseases. Our medicines are helping millions of patients around the world in disease areas such as oncology, cardiovascular, immunoscience, fibrosis and others. Through the Bristol-Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions, giving new hope to some of the world`s most vulnerable people. Each day, our employees around the world work together for patients – it drives everything we do.